COMPARATIVE STUDY TO CHECK THE EFFICACY OF pH STRIP & pH GLOVES FOR DETECTION OF BACTERIAL VAGINOSIS IN A TERTIARY CARE HOSPITAL

Objectives: Comparative study to check the efficacy of pH Strip & pH Gloves for Detection of Bacterial Vaginosis in a Tertiary Care Hospital.Methods: It was a duly approved, cross-sectional study in which 50 subjects were enrolled from Tertiary care hospital, New Delhi, India. Written informed consent was obtained from all women. Vaginal swabs were collected for vaginal pH measurement. Vaginal pH was evaluated immediately with the pH strips and vaginal pH glove simultaneously.Results: The study was done on to check the efficacy of pH strip & pH gloves in pregnant as well as non-pregnant women by regularly visiting the tertiary care hospital. Among 50 subjects 8(16%) were Pregnant and 42(84%) were Non-pregnant. The mean age of the patients included in the study was found to be 26.1±19.5 years. After a Gram stain and microscopic examination of samples obtained from 50 women, those with intermediate flora and Candida infection were excluded and the final analysis was done on 40 samples. Among 40, 15 were diagnosed with BV and 25 had normal vaginal flora based on Nugents' score.Conclusions: Our findings show that vaginal pH determination is relatively sensitive, but less specific in detecting women with BV. Both pH glove and pH strip are equally suitable for screening women with BV on an outpatient basis. Further studies are required to explore the possibility of self-evaluation of vaginal pH with pH glove at community level.Â

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

SummaryBackground Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatoryactions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospitalwith COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients wererandomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once perday by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatmentgroups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment andwere twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants andlocal study staff were not masked to the allocated treatment, but all others involved in the trial were masked to theoutcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treatpopulation. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) wereeligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomlyallocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall,561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days(rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days(rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, nosignificant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilationor death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24).Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or otherprespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restrictedto patients in whom there is a clear antimicrobial indication

Isolation and Characterization of Alpha and Nanocrystalline Cellulose from Date Palm (Phoenix dactylifera L.) Trunk Mesh

Highly pure cellulosic polymers obtained from waste lignocellulose offer great potential for designing novel materials in the concept of biorefinery. In this work, alpha-cellulose and nanocrystalline cellulose were isolated from the date palm trunk mesh (DPTM) through a series of physicochemical treatments. Supercritical carbon dioxide treatment was used to remove soluble extractives, and concentrated alkali pretreatment was used to eliminate the lignin portion selectively to obtain alpha-cellulose in approximately 94% yield. Further treatments of this cellulose yielded nanocrystalline cellulose. The structure–property relationship studies were carried out by characterizing the obtained polymers by various standard methods and analytical techniques such as Fourier transform infrared spectroscopy-attenuated total reflection (FTIR-ATR), thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), energy dispersive X-ray diffraction (EDX-XRD), scanning electron microscopy (SEM) and transmission electron microscopy (TEM). Almost 65% yield of pure cellulose was achieved, out of which 94% is the alpha-cellulose. This cellulose shows good thermal stability and crystallinity. The microscopic analysis of the nanocellulose showed a heterogeneous mix of irregular-shaped particles with a size range of 20–60 nm. The percentage crystallinity of alpha-cellulose and nanocellulose was found to be 68.9 and 71.8, respectively. Thus, this study shows that, this DPTM-based low-cost waste biomass can be a potential source to obtain cellulose and nano-cellulose